Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for InMed Pharmaceuticals (INM) over the last 3 years, with Q2 2024 value amounting to $42408.0.

  • InMed Pharmaceuticals' Asset Writedowns and Impairment rose 11583.36% to $42408.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $42408.0, marking a year-over-year increase of 105707.52%. This contributed to the annual value of $2424.0 for FY2025, which is 9920.74% down from last year.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment amounted to $42408.0 in Q2 2024, which was up 11583.36% from $170474.0 recorded in Q4 2023.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $576772.0 during Q3 2022, with a 5-year trough of -$267835.0 in Q2 2023.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $92930.0 (2023), whereas its average is $122949.8.
  • In the last 5 years, InMed Pharmaceuticals' Asset Writedowns and Impairment plummeted by 8388.79% in 2023 and then soared by 11583.36% in 2024.
  • Over the past 3 years, InMed Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $576772.0 in 2022, then crashed by 70.44% to $170474.0 in 2023, then crashed by 75.12% to $42408.0 in 2024.
  • Its Asset Writedowns and Impairment was $42408.0 in Q2 2024, compared to $170474.0 in Q4 2023 and $92930.0 in Q3 2023.